Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
histologically confirmed pancreatic cancer, virus-associated tumors [including papillomaviruses-related cancers (cervical, head and neck, and nasal), Epstein-Barr virus (nasopharyngeal carcinoma) and Kaposi's sarcoma-associated herpes virus), non-small cell lung cancer, soft-tissue sarcomas, bladder cancer, triple negative breast cancer. For population 4, diagnosis must be confirmed by the RRePS Network as recommended by the French NCI. For population 2, papillomavirus-related cancers must be eligible whatever the genotype but in case of viral genotype is not available, IHC p16 positive must be provided, hepatocellular carcinoma must be confirmed by Hepatite B or C infection, HHV-8 and Epstein-Barr virus related cancers must be confirmed by molecular analysis,
Metastatic disease,
Age ≥ 18 years,
ECOG ≤ 1,
Previous treatment with a TLR agonist
Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal metastases,
Women who are pregnant or breast feeding,
Participation in a study involving a medical or therapeutic intervention in the last 30 days,
6
Treatment groupsSee each treatment group below.
Institut Bergonié
Lead sponsor
Roche Pharma AG
Collaborator
National Cancer Institute, France
Collaborator
Eikon Therapeutics
Collaborator